Literature DB >> 1457193

Genetic and functional analysis of a set of HIV-1 envelope genes obtained from biological clones with varying syncytium-inducing capacities.

A C Andeweg1, M Groenink, P Leeflang, R E de Goede, A D Osterhaus, M Tersmette, M L Bosch.   

Abstract

To study HIV-1 envelope-mediated syncytium formation we have amplified, cloned, expressed, and sequenced individual envelope genes from a set of eight biological HIV-1 clones. These clones were obtained from two patients and display either a syncytium-inducing (SI) or nonsyncytium-inducing (NSI) phenotype. Upon expression through recombinant vaccinia virus, individual envelope gene products display heterogeneous syncytium-inducing capacities which reflect the phenotype of the parental biological HIV-1 clones in all cases. For the eight biological HIV-1 clones presented here, variation of the envelope gene alone is sufficient to explain the observed variable syncytium-inducing capacity of the respective parental viruses. In addition we determined the complete nucleotide sequence of these envelope genes. The predicted amino acid sequence revealed a considerable amount of variation located mainly in the previously denominated variable regions. In various regions of envelope genes obtained from the same patient, phenotype associated amino acid variation was found. This phenotype associated amino acid variation however, is not conserved between the two sets of envelope genes derived from different patients. Four envelope sequences derived from clones obtained from one patient showed phenotype-associated amino acid variation in the fusion domain. Sequencing of 12 additional fusion domains revealed that this same variation is found in four additional clones. However, a functional test performed on recombinant vaccinia expressing mutant envelope genes showed that this observed fusion domain variation does not contribute to the variation in syncytium-inducing capacity of the envelope gene product.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457193     DOI: 10.1089/aid.1992.8.1803

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  A point mutation in the env gene of a murine leukemia virus induces syncytium formation and neurologic disease.

Authors:  B H Park; B Matuschke; E Lavi; G N Gaulton
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

2.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

Authors:  E G Hulskotte; A M Geretti; K H Siebelink; G van Amerongen; M P Cranage; E W Rud; S G Norley; P de Vries; A D Osterhaus
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

3.  Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.

Authors:  Christophe Guillon; Martin Schutten; Patrick H M Boers; Rob A Gruters; Albert D M E Osterhaus
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Peripheral blood mononuclear cells from sheep infected with a variant of bovine leukemia virus synthesize envelope glycoproteins but fail to induce syncytia in culture.

Authors:  E R Johnston; M A Powers; L C Kidd; K Radke
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Authors:  Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.